Fondaparinux: Better than Enoxaparin for Patients with Acute Coronary Syndromes?
Freek Verheugt
Shamir Mehta of McMaster University told Audio Medica in Stockholm about the OASIS-5/MICHELANGELO results comparing the new anti-thrombotic therapy, fondaparinux, with enoxaparin among patients with acute coronary syndromes. For a comment on Shamir Mehta’s presentation at the ESC meeting, Audio Medica questioned Freek Verheugt of Nijmegen.
Shamir Mehta: [audio:https://www.audiomedica.com/podcasting/08.Shamir_Mehta.mp3]
Freek Verheugt: [audio:https://www.audiomedica.com/podcasting/09.Freek_Verheugt.mp3]
